Search | Clinical Trials Finder

Conditions: Irritable Bowel Syndrome
Interventions: Eluxadoline, Placebo; Drug
Lead sponsor: Furiex Pharmaceuticals, Inc; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 807 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2010 – 2011
U.S. locations: 288
States / cities: Anniston, Alabama • Birmingham, Alabama • Dothan, Alabama + 225 more

Conditions: Heart Failure, Systolic, Inflammation
Interventions: Anakinra, Placebo; Drug
Lead sponsor: Virginia Commonwealth University; Other
Eligibility: 21 Years and older
Enrollment: 102 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2024
U.S. locations: 1
States / cities: Richmond, Virginia

Conditions: Hepatitis C
Interventions: Candesartan, Placebo; Drug
Lead sponsor: Kaiser Permanente; Other
Eligibility: 21 Years to 65 Years
Healthy volunteers: Healthy volunteers not accepted
U.S. locations: 2
States / cities: Roseville, California • Sacramento, California

Conditions: Opioid Use, Pain, Postoperative
Interventions: Bupivacaine, Dexamethasone, Saline; Drug · Other
Lead sponsor: Hospital for Special Surgery, New York; Other
Eligibility: 18 Years to 80 Years
Enrollment: 46 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2022
U.S. locations: 1
States / cities: New York, New York

Conditions: Achilles Tendon Rupture, Blood Flow Restriction Therapy, Achilles Tendon Repairs/Reconstructions, Dynamic Blood Flow Restriction
Interventions: Blood Flow Restriction Resistance Training (BFR-RT), Sham Blood Flow Restriction, Standard Physical Therapy; Device · Behavioral
Lead sponsor: Massachusetts General Hospital; Other
Eligibility: 18 Years to 75 Years
Enrollment: 75 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2027
U.S. locations: 1
States / cities: Boston, Massachusetts

Conditions: Peripheral Artery Disease, Critical Limb Ischemia
Interventions: Temsirolimus, Saline placebo; Drug
Lead sponsor: Mercator MedSystems, Inc.; Industry
Eligibility: 18 Years and older
Enrollment: 250 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2025 – 2032
U.S. locations: 2
States / cities: Houma, Louisiana • Dallas, Texas

Conditions: Post Minimally Invasive Thorascopic Surgical Pain
Interventions: Bupivacaine and Dexamethasone, Placebo; Drug
Lead sponsor: Cedars-Sinai Medical Center; Other
Eligibility: 18 Years to 80 Years
Enrollment: 50 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2013 – 2015
U.S. locations: 1
States / cities: Los Angeles, California

Conditions: COPD (Chronic Obstructive Pulmonary Disease)
Interventions: WIN378, Placebo; Drug
Lead sponsor: Windward Bio; Industry
Eligibility: 40 Years to 80 Years
Enrollment: 105 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2026 – 2028
U.S. locations: 8
States / cities: Los Angeles, California • Miami Lakes, Florida • North Dartmouth, Massachusetts + 5 more

Conditions: Pulmonary Disease, Chronic Obstructive
Interventions: placebo to tiotropium + olodaterol, tiotropium +olodaterol, tiotropium; Drug
Lead sponsor: Boehringer Ingelheim; Industry
Eligibility: 40 Years to 75 Years
Enrollment: 304 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 3
States / cities: San Diego, California • Torrance, California • Hartford, Connecticut

Conditions: Overweight and Obesity, Insulin Resistance
Interventions: Placebo - Cap, Amiloride Pill; Drug
Lead sponsor: University of Missouri-Columbia; Other
Eligibility: 30 Years to 70 Years
Enrollment: 137 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2025
U.S. locations: 1
States / cities: Columbia, Missouri

Conditions: Breast Cancer Early Stage Breast Cancer (Stage 1-3)
Interventions: Fezolinetant, Placebo; Drug
Lead sponsor: Yale University; Other
Eligibility: 18 Years and older · Female only
Enrollment: 92 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2025 – 2028
U.S. locations: 2
States / cities: New Haven, Connecticut • Columbus, Ohio

Conditions: Actinic Keratosis, Basal Cell Carcinoma of the Skin, Recurrent Skin Cancer, Squamous Cell Carcinoma of the Skin
Interventions: liposomal T4N5 lotion, placebo, laboratory biomarker analysis; Drug · Other
Lead sponsor: National Cancer Institute (NCI); NIH
Eligibility: 19 Years and older
Enrollment: 100 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: Started 2004
U.S. locations: 1
States / cities: Birmingham, Alabama

Conditions: Alcohol Use Disorder (AUD)
Interventions: Doxazosin, Placebo; Drug
Lead sponsor: Brown University; Other
Eligibility: 18 Years and older
Enrollment: 184 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2019 – 2026
U.S. locations: 1
States / cities: Providence, Rhode Island

Conditions: Statin Intolerance
Interventions: Pure epicatechin capsules (50mg), Simvastatin (40mg), Placebo; Dietary Supplement · Drug · Other
Lead sponsor: University of California, San Diego; Other
Eligibility: 30 Years to 75 Years
Enrollment: 19 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2015 – 2021
U.S. locations: 1
States / cities: La Jolla, California

Conditions: Postsurgical Pain
Interventions: CA-008 5 mg, Placebo, Bupivacaine Hydrochloride, Hydromorphone, Fentanyl, Acetaminophen, Oxycodone, CA-008 10 mg, CA-008 15 mg; Drug
Lead sponsor: Concentric Analgesics; Industry
Eligibility: 18 Years to 65 Years
Enrollment: 54 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2019
U.S. locations: 1
States / cities: Pasadena, California

Conditions: Surgical Abortion, Patient Satisfaction, Anesthesia, Pain
Interventions: Placebo oil, Lavender oil.; Other
Lead sponsor: University of Colorado, Denver; Other
Eligibility: 18 Years to 50 Years · Female only
Enrollment: 144 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2021 – 2022
U.S. locations: 1
States / cities: Denver, Colorado

Conditions: Migraine
Interventions: Dexamethasone Oral, Placebo; Drug
Lead sponsor: Texas Tech University Health Sciences Center, El Paso; Other
Eligibility: 18 Years to 85 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2023 – 2028
U.S. locations: 1
States / cities: El Paso, Texas

Conditions: Contraception, Bleeding
Interventions: transdermal estradiol, naproxen, oral placebo; Drug
Lead sponsor: Washington University School of Medicine; Other
Eligibility: 18 Years to 45 Years · Female only
Enrollment: 129 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2008 – 2011
U.S. locations: 1
States / cities: St Louis, Missouri

Conditions: Catheter Occlusion, Thrombosis
Interventions: CUSA-081, Placebo, Alteplase; Drug
Lead sponsor: Chiesi Farmaceutici S.p.A.; Industry
Eligibility: 18 Years and older
Enrollment: 462 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2023
U.S. locations: 35
States / cities: Little Rock, Arkansas • Redlands, California • Stockton, California + 31 more

Conditions: Smoking Cessation
Interventions: Nadolol, Placebo; Drug
Lead sponsor: Invion, Inc.; Industry
Eligibility: 18 Years to 70 Years
Enrollment: 155 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2014 – 2015
U.S. locations: 4
States / cities: Phoenix, Arizona • Miami, Florida • St Louis, Missouri

Conditions: Oxidative Stress, Endothelial Dysfunction
Interventions: valsartan (ARB), ramipril (ACE inhibitor), Placebo; Drug
Lead sponsor: Vanderbilt University; Other
Eligibility: 18 Years and older
Enrollment: 78 participants
Healthy volunteers: Accepts healthy volunteers
Timeline: 2010 – 2015
U.S. locations: 1
States / cities: Nashville, Tennessee

Conditions: Autoimmune Hepatitis
Interventions: VAY736, Placebo; Biological · Other
Lead sponsor: Novartis Pharmaceuticals; Industry
Eligibility: 18 Years to 75 Years
Enrollment: 68 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2018 – 2025
U.S. locations: 4
States / cities: Coronado, California • Rialto, California • Sacramento, California + 1 more

Conditions: Glioblastoma, Recurrent Glioblastoma
Interventions: VB11, Surgery, Placebo, Bevacizumab; Drug · Procedure · Other
Lead sponsor: Dana-Farber Cancer Institute; Other
Eligibility: 18 Years and older
Enrollment: 15 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2020 – 2024
U.S. locations: 4
States / cities: Los Angeles, California • Boston, Massachusetts • San Antonio, Texas + 1 more

Conditions: Social Anxiety Disorder
Interventions: Attentional Bias Modification Training (ABMT), General Attention Control Training; Other
Lead sponsor: University of Wisconsin, Milwaukee; Other
Eligibility: 18 Years to 60 Years
Enrollment: 84 participants
Healthy volunteers: Healthy volunteers not accepted
Timeline: 2022 – 2024
U.S. locations: 1
States / cities: Milwaukee, Wisconsin

Search by objective public record fields.

Efficacy, Safety, and Tolerability of JNJ-27018966 (Eluxadoline) in the Treatment of Irritable Bowel Syndrome With Diarrhea

Interleukin-1 Blockade In Recently Decompensated Heart Failure - 2

Angiotensin Receptor Blockade as an Anti-Fibrotic Intervention in Patients With Chronic Hepatitis C

Erector Spinae Plane Block Versus Conventional Analgesia in Complex Spine Surgery

Project Tendura: The Impact of Blood Flow Restriction Resistance Training (BFR-RT) in Patients With Achilles Tendon Rupture (ATR) Repair

Temsirolimus Adventitial Delivery to Improve ANGioplasty and/or Atherectomy Revascularization Outcomes Below the Knee

The Effect of Dexamethasone on the Duration and Functionality of Bupivacaine Intercostal Nerve Blockade

A Study of WIN378 in Participants With Moderate to Severe COPD (Sirius)

To Evaluate the Effect of Inhaled Medication Together With Exercise and Activity Training on Exercise Capacity and Daily Activities in Patients With Chronic Lung Disease With Obstruction of Airways

ENAC Blockade and Arterial Stiffness

FLASH-Breast: Evaluating the Efficacy of Fezolinetant in Reducing Vasomotor Symptoms in Women With Breast Cancer on Endocrine Therapy

T4N5 Liposomal Lotion in Preventing The Recurrence of Nonmelanoma Skin Cancer in Patients Who Have Undergone a Kidney Transplant

Alpha-1 Blockade for Alcohol Use Disorder (AUD)

Effects of Epicatechin on Statins for Mitochondrial Dysfunction and Impaired Exercise Capacity

Study in Subjects Undergoing Complete Abdominoplasty

Effects of Aromatherapy on Patient Satisfaction With Surgical Abortion at Less Than 10 Weeks Gestation

Does Nerve Block + Oral Dexamethasone Reduce Recurrence of Headache Within 72 Hrs?

A Randomized Controlled Trial of Oral Naproxen and Transdermal Estradiol for Bleeding in LNG-IUC

Efficacy and Safety of CUSA-081 in the Restoration of Central Venous Access Device (CVAD) Functionality

Efficacy and Safety of Βeta-adrenoceptor Inverse Agonist and Biased Ligand, Nadolol, In Smoking Cessation of Patients With Chronic Cough With or Without Airflow Obstruction

Genes, Fibrinolysis and Endothelial Dysfunction- Dialysis Aim 3

ADCC Mediated B-Cell dEpletion and BAFF-R Blockade

VB-111 in Surgically Accessible Recurrent/Progressive GBM

Attention Bias Modification Training for Social Phobia (ABMSP)